Elizabeth A. Barrett - 31 Jan 2024 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Executive Officer
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
31 Jan 2024
Net transactions value
$0
Form type
4
Filing time
02 Feb 2024, 19:04:22 UTC
Previous filing
15 Jun 2023
Next filing
07 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Award $0 +87,615 $0.000000 87,615 31 Jan 2024 Ordinary Shares 87,615 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2025, January 31, 2026 and January 31, 2027.